PRESS RELEASES

PRESS RELEASES

Date Title and Summary Additional Formats
Toggle Summary ERYTECH to Present at the JMP Securities Hematology Summit
LYON, France and CAMBRIDGE, Mass., Dec. 10, 2020 (GLOBE NEWSWIRE) -- ERYTECH Pharma (Nasdaq & Euronext: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, announce d today that CEO, Gil Beyen, will
View HTML
Toggle Summary Monthly information related to total number of voting rights and shares composing the share capital – November 30, 2020
LYON, France, Dec. 10, 2020 (GLOBE NEWSWIRE) -- Article 223-16 of general regulation of French Autorité des Marchés Financiers Lyon – France Listing markets: Euronext Paris from Euronext (Market segment C - ISIN Code: FR0011471135- Symbol: ERYP) & Nasdaq Global Select Market in the United-States
View HTML
Toggle Summary ERYTECH Announces Positive Results from Eryaspase Phase 2 Trial in Acute Lymphoblastic Leukemia Presented at the American Society of Hematology Annual Meeting
W ebcast today, Monday, December 7 at 4:00 pm CET/10:00 am ET The study confirms the potential of eryaspase as an attractive treatment option for ALL patients with hypersensitivity to PEG-asparaginase LYON, France and CAMBRIDGE, Mass., Dec. 07, 2020 (GLOBE NEWSWIRE) -- ERYTECH Pharma (Nasdaq &
View HTML
Toggle Summary ERYTECH Announces Conference Webcast to Discuss Results from Eryaspase Phase 2 Trial in Acute Lymphoblastic Leukemia to be Presented at the American Society of Hematology 2020 Annual Meeting
Webcast scheduled for Monday, December 7 at 4:00 pm CET/10:00 am ET LYON, France and CAMBRIDGE, Mass., Dec. 03, 2020 (GLOBE NEWSWIRE) -- ERYTECH Pharma (Nasdaq & Euronext: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances
View HTML
Toggle Summary ERYTECH to Present at Jefferies Virtual Healthcare Conference
LYON, France and CAMBRIDGE, Mass., Nov. 12, 2020 (GLOBE NEWSWIRE) -- ERYTECH Pharma (Nasdaq & Euronext: ERYP), announced t o day that its CEO, Gil Beyen, will present an update at the Jefferies Virtual London Healthcare Conference at 12 :00 pm EST / 05:00pm GMT / 6 :00 pm CET on November 18, 2020.
View HTML
Toggle Summary ERYTECH Provides Business Update and Reports Financial Results for the Third Quarter of 2020
Conference call and webcast on Friday, November 6 at 2:30 pm CET/8:30 am ET TRYbeCA-1 Phase 3 trial in second-line metastatic pancreatic cancer: More than 9 5 % of the approximately 500 patients enrolled Number of events required for the interim superiority analysis has been reached Interim
View HTML
Toggle Summary ERYTECH Announces Abstract with Results from Eryaspase Phase 2 Trial in Acute Lymphoblastic Leukemia Selected for Oral Presentation at the American Society of Hematology 2020 Annual Meeting
Oral presentation to discuss f indings from the Nordic Society of Paediatric Haematology and Oncology ( NOPHO ) - sponsored Phase 2 trial that confirm the potential of e ryaspase as a treatment option for ALL Second abstract of n ew analysis supporting p opulation p harmacokinetics of e ryaspase in
View HTML
Toggle Summary Monthly information related to total number of voting rights and shares composing the share capital – October 31, 2020.
Article 223-16 of general regulation of French Autorité des Marchés Financiers LYON, France, Nov. 04, 2020 (GLOBE NEWSWIRE) -- Listing markets: Euronext Paris from Euronext (Market segment C - ISIN Code: FR0011471135- Symbol: ERYP) & Nasdaq Global Select Market in the United-States (Symbol : ERYP)
View HTML
Toggle Summary ERYTECH Secures €10 Million in Non-Dilutive Financing, Guaranteed by the French Government
Approvals received from Bpifrance and Société Générale for a total of EUR 10 million in non-dilutive financing in the form of a State- Guarantee d Loan (PGE Loan) Proceeds expected to extend Company’s cash horizon to end of 2021 LYON, France and CAMBRIDGE, Mass., Nov.
View HTML
Toggle Summary ERYTECH to Host Third Quarter 2020 Conference Call and Business Update on November 6, 2020
LYON, France, Oct. 29, 2020 (GLOBE NEWSWIRE) -- ERYTECH Pharma (Euronext Paris : ERYP - Nasdaq: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells , t oday announced that it will host a Third Quarter
View HTML
Top